The enhanced antitumor responses of PTPN22-deficient T cells were associated with elevated reactivity to low-affinity tumor antigens and a decreased susceptibility to inhibition by tumor-derived TGF-β (8). This evidence concerns the gene PTPN22 and neoplasm.